ArticleFrontiers in oncology2026
From patient-derived tumor organoids to personalized cancer therapy: advancing treatment for advanced solid tumors.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Cancer remains a major global public health burden, with high morbidity and mortality. Despite advances in treatment strategies, many patients with advanced solid tumors face treatment resistance and limited therapeutic options. Patient-derived tumor organoids (PDTOs) have emerged as promising preclinical models for personalized medicine, but their clinical translational potential in guiding individualized treatment for advanced solid tumors requires further validation. Methods: The sample data of 164 solid tumors used for establishing organoids were retrospectively analyzed, and a clinical cohort involving 23 patients with advanced solid tumors was used to validate the feasibility of PDTOs in predicting the treatment response. The concordance between PDTO drug responses and clinical outcomes was evaluated using Cohen's Kappa test. Results: The overall establishment success rate of organoids reached 91.5%, with the rates ranging from 90.6% to 92.6% across different cancer types. Histopathological analysis confirmed that PDTOs partially recapitulated the histopathological features and proliferative activity of matched original tumors. PDTO-based drug sensitivity testing showed good concordance with clinical treatment outcomes of patients with advanced solid tumors, yielding an overall accuracy of 85.0%, a sensitivity of 86.7%, a specificity of 80.0%. Clinical case studies further highlighted the unique value of PDTOs in overcoming multidrug resistance in advanced solid tumors. Conclusions: This study demonstrates that PDTOs exhibit favorable potential for predicting treatment responses in patients with advanced solid tumors, and may serve as a promising auxiliary companion diagnostic tool to inform personalized cancer therapy and assist in evaluating multidrug resistance for advanced solid tumors. Future large-scale, multicenter studies with stratified subgroup validations are warranted to further verify the clinical translational value of PDTOs in individualized tumor treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.